Lerario AM, Worden FP, Ramm CA, Hsseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The Combination of insulin-like growth factor receptor 1 (IGFR) antibody cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial. Horm Cancer. 2014 Aug; 5 (4) 232-9
Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78 (1) 76-80
Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drug. 2012 Feb; 30 (1): 382-6
Nimeiri, H , Oza A, Morgan R, Huo D, Elit L, Knost J, Wade J, Agamah E, Vokes E, Fleming G A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma: A Trial of the Chicago, PMH and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117 (1) 37-40
Ryan C, Dolan M, Brockstein B, McLendon, R, Delaney, S, Samuels, B, Agamah E, Vokes E.[My paper] A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer chemotherapy Pharmacology 2006 Nov; 58 (5) 634-9
The Combination of insulin-like growth factor receptor 1 (IGFR) antibody cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial; Cediranib in patients with malignant mesothelioma; Gemcitabine plus sorafenib in patients with advanced pancreatic cancer; A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma; and A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
